Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AAPS PharmSciTech ; 20(8): 312, 2019 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-31529266

RESUMO

To enhance efficiency, convenience, and safety of Parkinson's disease (PD) treatment for geriatric patients, an advanced suspension of Levodopa/Benserazide hydrochloride (LD/BH) has been prepared by cation-exchange resin and used to synchronize sustained release of LD and BH by optimizing coating parameters and prescription. For the purpose, LD and BH were immobilized on the surface of cation-exchange resin, respectively. Based on HPLC results, the cation-exchange resin showed high loading capacity. The studies on drug loading mechanism indicated that both drugs were immobilized by electrostatic interaction rather than physical adsorption. After PEG modification, pretreated drug-resin complexes were coated by emulsion-solvent evaporation method. In order to control drug release in a sustained manner, coating parameters of drug-resin microcapsules were optimized respectively by single-factor analysis. Further, coating prescription of the microcapsules was optimized to synchronize sustained release of LD and BH in vitro by orthogonal design. Utilizing optimal LD-resin microcapsules and BH-resin microcapsules, LD/BH suspension, containing both of them, was prepared by an optimal formulation and characterized by accelerated test and pharmacokinetic study in vivo. The accelerated test confirmed high stability of LD/BH suspension. According to pharmacokinetic results in vivo, in contrast with LD/BH commercial tablets, LD/BH suspensions did not only synchronize sustained release of both drugs but also show good bioequivalence. As LD/BH sustained release suspension can synchronize sustained release of multiple active ingredients by oral administration, the suspension presents promising oral dosage forms for geriatric patients with PD. An advanced Levodopa/Benserazide hydrochloride (LD/BH) suspension, prepared by cation-exchange resin and optimized microencapsulation, synchronizes sustained releases of LD and BH in vivo to benefit Parkinson's disease treatment for geriatric patients.


Assuntos
Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/química , Benserazida/administração & dosagem , Benserazida/química , Levodopa/administração & dosagem , Levodopa/química , Administração Oral , Animais , Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Cápsulas , Resinas de Troca de Cátion , Preparações de Ação Retardada , Combinação de Medicamentos , Composição de Medicamentos , Levodopa/farmacocinética , Lipídeos/química , Masculino , Ratos , Suspensões , Comprimidos com Revestimento Entérico
2.
Br J Clin Pharmacol ; 85(11): 2605-2613, 2019 11.
Artigo em Inglês | MEDLINE | ID: mdl-31378952

RESUMO

AIMS: While several generic preparations of levodopa/carbidopa and levodopa/benserazide (LBD) are currently available, pharmacokinetic (PK) equivalence and therapeutic equivalence studies with levodopa generics are not available in Italy. Lack of data on generic formulations is a critical factor for their limited use in this country and often lead patients to refuse the generic version of the branded drug. METHODS: An experimental, 2-centre, randomized, double-blind, 2-sequence, noninferiority cross-over study was designed to evaluate both the PK equivalence and clinical equivalence of multiple doses of the generic preparation of LDB, Teva Italia, compared to the originator (Madopar). Forty-three out-patients with a diagnosis of idiopathic Parkinson's disease on LDB, were recruited and randomly assigned to 1 of 2 study sequences: generic-originator or originator-generic. Clinical evaluations were performed at the end of each study period. A PK study with an LDB fixed dose (100 + 25 mg) was performed in a subpopulation of 14 subjects. RESULTS: Clinical data showed a reduction of 0.49 and 1.54 in the mean UPDRS III scores for the LDB and the originator, respectively. The 95% CIs [-2.21: 0.11] of the mean difference original vs LDB are smaller than the clinically significant difference of 3 UPDRS III points, supporting the conclusion that the treatment with LDB is not inferior to the originator. No statistically significant differences were found with respect to area under the curve to last dose, half-life, maximum concentration, time to maximum concentration and last observed concentration. CONCLUSION: These findings prove the therapeutic clinical equivalence as well the PK equivalence of the generic LDB and the originator (Madopar).


Assuntos
Benserazida/farmacocinética , Dopaminérgicos/farmacocinética , Medicamentos Genéricos/farmacocinética , Levodopa/farmacocinética , Doença de Parkinson/tratamento farmacológico , Adulto , Idoso , Benserazida/administração & dosagem , Benserazida/efeitos adversos , Estudos Cross-Over , Dopaminérgicos/administração & dosagem , Dopaminérgicos/efeitos adversos , Método Duplo-Cego , Combinação de Medicamentos , Medicamentos Genéricos/administração & dosagem , Medicamentos Genéricos/efeitos adversos , Humanos , Levodopa/administração & dosagem , Levodopa/efeitos adversos , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/sangue , Doença de Parkinson/diagnóstico , Índice de Gravidade de Doença , Resultado do Tratamento
3.
AAPS PharmSciTech ; 19(7): 2843-2850, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29845498

RESUMO

Despite extensive research in the field of gastroretentive dosage forms, this "holy grail" of oral drug delivery yet remained an unmet goal. Especially under fasting conditions, the reproducible retention of dosage forms in the stomach seems to be an impossible task. This is why such systems are often advised to be taken together with food. But also the postprandial motility can contribute significantly to the failure of gastroretentive dosage forms. To investigate the influence of postprandial pressure conditions on drug release from such systems, we used a novel in vitro dissolution tool, the dissolution stress test device. With the aid of this device, we simulated three different intragastric pressure profiles that may occur after postprandial intake. These transit scenarios were based on recently obtained, postprandial SmartPill® data. The tested systems, Glumetza® 1000 and Madopar® HBS 125, are marketed dosage forms that are based on different approaches to achieve proper gastric retention. All three transit scenarios revealed a highly pressure-sensitive drug release behavior, for both drugs. For Madopar® HBS 125, nearly complete drug release was observed even after early occurring pressures. Glumetza® 1000 seemed to be more resistant to these, most likely due to incomplete wetting of the system. On the contrary to these findings, data from standard dissolution tests using the paddle apparatus displayed controlled drug release for both systems for about 6 h. Based on these results, it can be doubted that established gastroretentive systems stay intact over a longer period of time, even under postprandial conditions.


Assuntos
Benserazida/farmacocinética , Liberação Controlada de Fármacos/fisiologia , Levodopa/farmacocinética , Período Pós-Prandial/fisiologia , Estômago/fisiologia , Benserazida/administração & dosagem , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/metabolismo , Formas de Dosagem , Combinação de Medicamentos , Sistemas de Liberação de Medicamentos/métodos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacocinética , Jejum/metabolismo , Humanos , Levodopa/administração & dosagem , Período Pós-Prandial/efeitos dos fármacos , Pressão , Estômago/efeitos dos fármacos
4.
Br J Clin Pharmacol ; 83(3): 540-553, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27763682

RESUMO

AIMS: To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa. METHODS: Two randomized, double blind, sex-balanced, placebo-controlled studies in four groups of 12 or 18 healthy subjects each. In each group, enrolled subjects received a once-daily morning (5, 15 and 30 mg) or evening (5, 15 and 50 mg) administration of OPC or placebo for up to 28 days. On the morning of Day 11, 12 h after the OPC or placebo evening dose, or the morning of Day 21, 1 h after the OPC or placebo dose, a single dose of immediate-release 100/25 mg LC was administered. Similarly, on Day 18 morning, 12 h after the OPC or placebo evening dose, or Day 28 morning, 1 h after the OPC or placebo dose, a single dose of immediate-release 100/25 mg LB was administered. RESULTS: All OPC treatments, in relation to the placebo group, presented a higher extent of exposure (AUC) to levodopa following either LC or LB doses. A relevant but not dose-dependent increase in the levodopa AUC occurred with all OPC dose groups in relation to placebo. All active treatments significantly inhibited both peak (Emax ) and extent (AUEC) of the catechol-O-methyltransferase activity in relation to placebo. The tolerability profile was favourable. CONCLUSION: Opicapone, as once-daily oral evening regimen and/or 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, long-lasting and sustained catechol-O-methyltransferase inhibition. The tolerability profile was favourable and similar between OPC and placebo.


Assuntos
Benserazida/farmacocinética , Levodopa/farmacocinética , Oxidiazóis/farmacologia , Oxidiazóis/farmacocinética , Adulto , Antiparkinsonianos/farmacocinética , Benserazida/efeitos adversos , Benserazida/sangue , Benserazida/farmacologia , Disponibilidade Biológica , Carbidopa/efeitos adversos , Carbidopa/farmacologia , Inibidores de Catecol O-Metiltransferase/efeitos adversos , Inibidores de Catecol O-Metiltransferase/sangue , Inibidores de Catecol O-Metiltransferase/farmacocinética , Inibidores de Catecol O-Metiltransferase/farmacologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Humanos , Levodopa/efeitos adversos , Levodopa/sangue , Levodopa/farmacologia , Masculino , Pessoa de Meia-Idade , Oxidiazóis/efeitos adversos , Oxidiazóis/sangue
5.
J Neurol ; 263(2): 250-256, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26566913

RESUMO

The differential diagnosis between multiple system atrophy with predominant parkinsonism (MSA-P) and Parkinson's disease (PD) may be challenging at disease onset. Levodopa responsiveness helps distinguish the two groups, but studies evaluating this issue using objective standardized tests are scanty. We retrospectively examined the extent of levodopa response by an objective kinetic-dynamic test in a series of patients prospectively followed up for a parkinsonian syndrome and eventually diagnosed as MSA-P or PD. Sixteen MSA-P and 31 PD patients under chronic levodopa therapy received a first morning fasting dose of levodopa/benserazide (100/25 mg) or levodopa/carbidopa (125/12.5 or 100/25 mg) and underwent simultaneous serial assessments of plasma levodopa concentration and alternate finger tapping frequency up to 3 h post dosing. The main levodopa pharmacodynamic variables were the maximum percentage increase in tapping frequency over baseline values (ΔTapmax %) and the area under the tapping effect-time curve (AUCTap). Levodopa pharmacokinetics did not show significant differences between MSA-P and PD, whereas both the magnitude and overall extent of levodopa tapping effect were markedly reduced in the MSA-P group (p < 0.001). The combined use of specific cut-off values for both the main pharmacodynamic variables, ΔTapmax % <20% and AUCTap <1900 [(tapping/min)·min], correctly discriminated 15 out of 16 MSA-P patients from PD patients. A combined estimation of these pharmacodynamic variables after a subacute low levodopa dose may be a simple and practical clinical tool to aid the differential diagnosis between MSA-P and PD.


Assuntos
Dopaminérgicos/farmacocinética , Levodopa/farmacocinética , Atrofia de Múltiplos Sistemas/diagnóstico , Doença de Parkinson/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Benserazida/farmacocinética , Diagnóstico Diferencial , Dopaminérgicos/sangue , Combinação de Medicamentos , Feminino , Humanos , Levodopa/sangue , Masculino , Pessoa de Meia-Idade , Atividade Motora/efeitos dos fármacos , Estudos Retrospectivos
6.
Clin Neuropharmacol ; 38(5): 201-3, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26366963

RESUMO

OBJECTIVES: We compared levodopa (LD) kinetic-dynamic profile of a dose of LD/aromatic amino acid decarboxylase peripheral inhibitors versus a nominally equivalent dose of a commercial Mucuna pruriens (Mucuna) seeds extract in 2 patients with Parkinson disease chronically taking LD standard combined with self-prescribed Mucuna. METHODS: Patients were challenged with a fasting morning dose of 100 mg LD/25 mg carbidopa (patient 1) or benserazide (patient 2) versus 100 mg LD from Mucuna capsules in 2 different sessions, after a 12-hour standard LD formulations' washout. They underwent kinetic-dynamic LD monitoring based on LD dose intake and simultaneous serial assessments of plasma drug concentrations and motor test performances. Quantitative analysis of LD in Mucuna capsules was also performed. RESULTS: Levodopa bioavailability was markedly lower after Mucuna administration compared with LD standard formulations: in patient 1, peak plasma LD concentration (Cmax) decreased from 2.0 to 1.0 mg/L and the area under the plasma concentration time curve from 137 to 33.6 mg/L per minute; in patient 2, Cmax was 0.7 mg/L after LD/benserazide and nearly undetectable after Mucuna. In patient 1, impaired LD bioavailability from Mucuna resulted in reduced duration and overall extent of drug response compared with LD/carbidopa. In patient 2, no significant subacute LD motor response was observed in either condition. Quantitative analysis of Mucuna formulation confirmed the 100 mg LD content for the utilized capsules. CONCLUSIONS: Our results show an impaired LD bioavailability from Mucuna preparation, as expected by the lacking aromatic amino acid decarboxylase inhibitors coadministration, which might explain the suggested lower dyskinetic potential of Mucuna compared with standard LD formulations.


Assuntos
Benserazida/farmacologia , Carbidopa/farmacologia , Levodopa/farmacocinética , Mucuna/química , Doença de Parkinson/tratamento farmacológico , Fitoterapia/métodos , Extratos Vegetais/farmacologia , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/farmacologia , Benserazida/administração & dosagem , Benserazida/farmacocinética , Disponibilidade Biológica , Cápsulas , Carbidopa/administração & dosagem , Carbidopa/farmacocinética , Quimioterapia Combinada , Feminino , Interações Ervas-Drogas , Humanos , Levodopa/farmacologia , Masculino , Pessoa de Meia-Idade , Destreza Motora/efeitos dos fármacos , Doença de Parkinson/metabolismo , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacocinética , Sementes/química
7.
Sci Rep ; 4: 3730, 2014 Jan 16.
Artigo em Inglês | MEDLINE | ID: mdl-24429495

RESUMO

L-dopa remains the mainstay treatment for Parkinson's disease (PD), although in later stages, treatment is complicated by L-dopa-induced dyskinesias (LID). Current evidence links LID to excessive striatal L-dopa-derived dopamine (DA) release, while the possibility of a direct involvement of L-dopa itself in LID has been largely ignored. Here we show that L-dopa can alter basal ganglia activity and produce LID without enhancing striatal DA release in parkinsonian non-human primates. These data may have therapeutic implications for the management of advanced PD since they suggest that LID could result from diverse mechanisms of action of L-dopa.


Assuntos
Dopaminérgicos/efeitos adversos , Discinesias/etiologia , Levodopa/efeitos adversos , 1-Metil-4-Fenil-1,2,3,6-Tetra-Hidropiridina/efeitos adversos , Animais , Benserazida/efeitos adversos , Benserazida/farmacocinética , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , Modelos Animais de Doenças , Dopamina/metabolismo , Dopaminérgicos/farmacocinética , Combinação de Medicamentos , Discinesias/metabolismo , Feminino , Levodopa/farmacocinética , Macaca mulatta , Masculino , Doença de Parkinson/metabolismo
8.
BMC Pharmacol Toxicol ; 14: 24, 2013 Apr 23.
Artigo em Inglês | MEDLINE | ID: mdl-23617953

RESUMO

BACKGROUND: By definition, a generic product is considered interchangeable with the innovator brand product. Controversy exists about interchangeability, and attention is predominantly directed to contaminants. In particular for chronic, degenerative conditions such as in Parkinson's disease (PD) generic substitution remains debated among physicians, patients and pharmacists. The objective of this study was to compare the pharmaceutical quality of seven generic levodopa/benserazide hydrochloride combination products marketed in Germany with the original product (Madopar® / Prolopa® 125, Roche, Switzerland) in order to evaluate the potential impact of Madopar® generics versus branded products for PD patients and clinicians. METHODS: Madopar® / Prolopa® 125 tablets and capsules were used as reference material. The generic products tested (all 100 mg/25 mg formulations) included four tablet and three capsule formulations. Colour, appearance of powder (capsules), disintegration and dissolution, mass of tablets and fill mass of capsules, content, identity and amounts of impurities were assessed along with standard physical and chemical laboratory tests developed and routinely practiced at Roche facilities. Results were compared to the original "shelf-life" specifications in use by Roche. RESULTS: Each of the seven generic products had one or two parameters outside the specifications. Deviations for the active ingredients ranged from +8.4% (benserazide) to -7.6% (levodopa) in two tablet formulations. Degradation products were measured in marked excess (+26.5%) in one capsule formulation. Disintegration time and dissolution for levodopa and benserazide hydrochloride at 30 min were within specifications for all seven generic samples analysed, however with some outliers. CONCLUSIONS: Deviations for the active ingredients may go unnoticed by a new user of the generic product, but may entail clinical consequences when switching from original to generic during a long-term therapy. Degradation products may pose a safety concern. Our results should prompt caution when prescribing a generic of Madopar®/Prolopa®, and also invite to further investigations in view of a more comprehensive approach, both pharmaceutical and clinical.


Assuntos
Benserazida/normas , Cápsulas/normas , Medicamentos Genéricos/normas , Levodopa/normas , Comprimidos/normas , Benserazida/farmacocinética , Benserazida/uso terapêutico , Cápsulas/química , Cor , Dopaminérgicos/farmacocinética , Dopaminérgicos/normas , Dopaminérgicos/uso terapêutico , Combinação de Medicamentos , Medicamentos Genéricos/farmacocinética , Medicamentos Genéricos/uso terapêutico , Humanos , Levodopa/farmacocinética , Levodopa/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Padrões de Prática Médica/normas , Vigilância de Produtos Comercializados/métodos , Vigilância de Produtos Comercializados/estatística & dados numéricos , Controle de Qualidade , Comprimidos/química , Equivalência Terapêutica
9.
Clin Neuropharmacol ; 35(3): 111-7, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22549097

RESUMO

OBJECTIVES: To compare bioavailability and pharmacokinetics of single doses of 3 different levodopa formulations given orally in healthy volunteers. Two marketed formulations, standard levodopa/carbidopa, 100/25 mg (LC-100), and dispersible levodopa/benserazide, 100/25 mg (LB-100), were used as reference formulations for a newly developed dispersible microtablet formulation of levodopa/carbidopa, 5/1.25 mg (LC-5). The microtablets are intended for individualized dosing of levodopa/carbidopa in Parkinson disease by means of an electronic dose dispenser with a built-in diary for symptom registration. METHODS: A single-dose, open, randomized, 3-way crossover study was performed in 19 healthy subjects. Concentrations of levodopa, carbidopa, and the metabolite 3-O-MD in plasma were determined after intake of 100 mg of levodopa, that is, one tablet of reference formulations and 20 microtablets of the new formulation. RESULTS: The LC-5 microtablets were bioequivalent to the LC-100 tablets in area under the curve (AUC) and maximum concentration in plasma (Cmax) for levodopa, and to the LB-100 tablets in AUC. The dispersible levodopa/benserazide formulation showed earlier time to Cmax and significantly higher Cmax for levodopa in plasma compared to the microtablets. Carbidopa showed larger interindividual variation in AUC and Cmax than levodopa, and the bioequivalence comparison LC-5/LC-100 for this compound did not reach the target. Nevertheless, comparison of 3-O-MD levels for LC-5/LC-100, assuming proportionality to levodopa levels, demonstrated bioequivalence. CONCLUSIONS: The new levodopa/carbidopa microtablets had a pharmacokinetic profile that would allow for a convenient switch of therapy from standard tablets. Frequent dose administration of levodopa/carbidopa microtablets with an electronic dose dispenser might offer an optimal oral drug delivery in Parkinson disease.


Assuntos
Benserazida/administração & dosagem , Benserazida/farmacocinética , Carbidopa/administração & dosagem , Carbidopa/farmacocinética , Levodopa/administração & dosagem , Levodopa/farmacocinética , Adulto , Estudos Cross-Over , Combinação de Medicamentos , Feminino , Seguimentos , Humanos , Masculino , Comprimidos , Adulto Jovem
10.
J Pharm Biomed Anal ; 56(5): 1094-100, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-21856105

RESUMO

A sensitive and simple method was developed for the quantitation of levodopa and its metabolite 3-O-methyldopa, in human plasma, after oral administration of tablet formulations containing levodopa (200 mg) and benserazide (50 mg). The analytes were extracted by a protein precipitation procedure, using carbidopa as an internal standard. A mobile phase consisting of 0.2% formic acid and acetonitrile (94:6, v/v) was used and chromatographic separation was achieved using ACE C(18) column (50 mm×4.6 mm i.d.; 5 µm particle size). Selected reaction monitoring was performed using the fragmentation transitions m/z 198→m/z 107, m/z 212→m/z 166 and m/z 227→m/z 181 for levodopa, 3-O-methyldopa and carbidopa, respectively. Calibration curves were constructed over the range 50.0-6000.0 ng/mL for levodopa and 25.0-4000.0 ng/mL for 3-O-methyldopa. The method shown to be specific, precise, accurate and provided recovery rates higher than 85% for all analytes. No matrix effect was detected in the samples. The validated method was applied in a pharmacokinetic study with a levodopa/benserazide tablet formulation in healthy volunteers.


Assuntos
Benserazida/sangue , Cromatografia Líquida de Alta Pressão/métodos , Levodopa/sangue , Metildopa/sangue , Espectrometria de Massas por Ionização por Electrospray/métodos , Espectrometria de Massas em Tandem/métodos , Benserazida/farmacocinética , Calibragem , Humanos , Levodopa/farmacocinética , Metildopa/farmacocinética , Controle de Qualidade , Reprodutibilidade dos Testes , Comprimidos
11.
Clin Ther ; 33(4): 500-10, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21635995

RESUMO

BACKGROUND: Currently, levodopa administered with decarboxylase inhibitors is the gold standard for the management of the motor symptoms of Parkinson's disease, a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta. In Argentina, only 1 commercial product is available with such composition; this study was contracted by the manufacturer to comply with new generic product regulations. OBJECTIVE: The aim of this study was to evaluate the fasting bioavailability of a new generic formulation of levodopa 200 mg/benserazide 50 mg tablets (test) and compare this generic formulation with the branded formulation (reference) to meet regulatory criteria for marketing the test product in Argentina. METHODS: A randomized-sequence, open-label, 2-period, crossover study was conducted between August and October 2009 in healthy Caucasian volunteers (n = 24; 18 males, aged 21 to 42 years, with a body mass index ranging from 19.7 to 26.0 kg/m(2)) in the fasted state. A single oral dose of the test or reference formulation was administered, and after a 7-day washout period, the other formulation was given. Blood samples were collected at baseline and at 10, 20, 30, 40, 50, 60, 70, 80, 90, and 105 minutes and 2, 2.5, 3, 3.5, 4, and 6 hours after dosing. Levodopa plasma concentrations were measured by high-performance liquid chromatography with electrochemical detection, without stereo-specificity assessment. The formulations were considered bioequivalent if the 90% CI of the geometric mean ratios (test/reference) for the C(max) and AUC(0-t) of levodopa were within the 0.8 to 1.25 range. Adverse events were monitored throughout the study, based on clinical parameters and patient reports. RESULTS: The geometric means (90% CI) of the C(max) for the test and reference formulations were 2462.02 (2312.06-3492.40) and 2542.85 (2394.49-3231.29) ng/mL, respectively; the AUC(0-t) was 3878.04 (3623.88-5393.09) and 3972.10 (3765.88-5393.02) ng/mL/h, respectively; and the AUC(0-∞)was 4610.37 (4315.71-6315.70) and 4728.96 (4502.17-6828.26) ng/mL/h, respectively. There were no significant differences in pharmacokinetic parameters between the 2 formulations. The test:reference ratios for C(max), AUC(0-t), and AUC(0-∞) were 96.82% (90% CI, 83.87-111.77), 97.63% (90% CI, 85.95-110.91), and 97.49% (90% CI, 84.09-113.02), respectively. No clinically significant adverse events were reported; this finding is probably the result of subjects not believing that their side effects were severe enough to be reported and not because of a genuine and absolute lack of predictable side effects. CONCLUSIONS: In this single-dose study, the test formulation of levodopa/benserazide tablets met the Argentinean criterion for bioequivalence to the reference formulation. (www.clinicaltrials.gov: NCT01327261).


Assuntos
Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Medicamentos Genéricos/farmacocinética , Levodopa/farmacocinética , Administração Oral , Adulto , Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/efeitos adversos , Área Sob a Curva , Argentina , Benserazida/administração & dosagem , Benserazida/efeitos adversos , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Combinação de Medicamentos , Medicamentos Genéricos/administração & dosagem , Medicamentos Genéricos/efeitos adversos , Feminino , Humanos , Levodopa/administração & dosagem , Levodopa/efeitos adversos , Masculino , Comprimidos , Equivalência Terapêutica , Adulto Jovem
12.
J Pharm Sci ; 99(1): 227-33, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19455628

RESUMO

To study the effect of varied intestinal delivery of levodopa ester, levodopa and its butyl ester were administered as bolus or continuous infusions into site-specific, in situ ligated intestinal loops of rats. Benserazide, a carboxylase inhibitor, was not administered, coadministered with ester, or infused into the duodenal loop prior to ester dosing. While the proximal colon minimally absorbed levodopa itself, it substantially absorbed the ester. Coadministration of benserazide and ester at the colon did not increase absorption; however, prior infusion of benserazide into the duodenum enhanced the colonic absorption of ester. Compared to bolus infusion, continuous delivery of the ester resulted in a more sustained levodopa concentration in plasma, and less metabolism into dopamine. The results were repeated for methyl ester, and the relative differences between the results of methyl and butyl esters versus levodopa were similar. The overall results at the duodenum, jejunum, and ileum were also comparable, likewise were those for the proximal, middle, and distal colons. The results of the study are encouraging: a combination of the continuous delivery of levodopa ester with an immediate-release of benserazide optimizes levodopa bioavailability, potentially leading to a much more effective use of levodopa in the treatment of Parkinson's patients.


Assuntos
Antiparkinsonianos/administração & dosagem , Benserazida/administração & dosagem , Mucosa Intestinal/metabolismo , Levodopa/análogos & derivados , Animais , Antiparkinsonianos/química , Antiparkinsonianos/farmacocinética , Benserazida/química , Benserazida/farmacocinética , Preparações de Ação Retardada , Combinação de Medicamentos , Estudos de Viabilidade , Bombas de Infusão , Absorção Intestinal , Intestinos/efeitos dos fármacos , Levodopa/administração & dosagem , Levodopa/química , Levodopa/farmacocinética , Masculino , Ratos , Ratos Sprague-Dawley , Distribuição Tecidual
13.
Clin Ther ; 31(10): 2258-71, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19922897

RESUMO

BACKGROUND: Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor. Coadministration of a COMT inhibitor with levodopa and a dopa-decarboxylase inhibitor (carbidopa or benserazide) increases levodopa exposure and its therapeutic effect. OBJECTIVES: The primary objective of this study was to investigate the effect of nebicapone (50, 100, and 200 mg), compared with placebo, on levodopa pharmacokinetics when coadministered with a single dose of controlled-release levodopa 100 mg/benserazide 25 mg. The secondary objectives were to investigate the effect of nebicapone on the erythrocyte-soluble COMT (S-COMT) activity and on the plasma levels of the levodopa 3-O-methylated metabolite (3-O-methyldopa [3-OMD]). Nebicapone's tolerability was also assessed. METHODS: This was a single-center, Phase I, doubleblind, randomized, placebo-controlled, 4-way crossover study conducted in healthy adult volunteers. Each of the 4 single-dose treatment periods was separated by a washout period of > or = 5 days. During the different treatment periods, subjects received a single dose of controlled-release levodopa 100 mg/benserazide 25 mg concomitantly with nebicapone 50, 100, and 200 mg or placebo. Plasma concentrations of nebicapone, levodopa, and 3-OMD were determined by HPLC. Blood samples (7 mL) for determination of plasma concentrations of levodopa, 3-OMD, and 2258 nebicapone, as well as for the assay of S-COMT activity, were collected in potassium EDTA test tubes at the following times: predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose. S-COMT activity was assessed as the amount of metanephrine formed by the action of S-COMT on an epinephrine substrate. Spontaneously reported clinical adverse events (AEs) were recorded throughout the study. RESULTS: Sixteen subjects (8 females, 8 males; mean [SD] age, 26.13 [6.29] years; weight, 69.4 [12.4] kg; body mass index, 24.0 [3.0] kg/m2) completed the 4 treatment periods and had data available for pharmacokinetic and pharmacodynamic analyses. Compared with placebo, levodopa C(max) increased 25%, 30%, and 34%, and AUC increased 14%, 37%, and 42% after administration of nebicapone 50, 100, and 200 mg, respectively. After administration of nebicapone 50, 100, and 200 mg, 3-OMD C(max) decreased 44%, 57%, and 58%, and 3-OMD AUC(0-infinity) decreased 33%, 37%, and 45%, respectively, compared with placebo. Extent of exposure to levodopa, as assessed by using AUC(0-t), increased with all doses of nebicapone in relationship to placebo, but the difference did not reach statistical significance. This may be related to a relatively high inter-subject variability: %CVs ranged from 48.0% with nebicapone 100 mg to 66.8% with placebo. Maximum S-COMT inhibition by nebicapone occurred at approximately 1.5 hours postdose and ranged from 57% with nebicapone 50 mg to 74% with nebicapone 200 mg. There was an inverse correlation between plasma concentrations of nebicapone and S-COMT activity; T(max) of nebicapone plasma concentrations and time to occurrence of the maximum inhibition of S-COMT activity appeared to correlate. Nineteen AEs were reported; 8 were assessed by the investigator as possibly related to treatment. All AEs were mild in severity. There were no serious AEs or discontinuations due to AEs. No abnormalities in liver enzyme levels were found. CONCLUSIONS: When administered concomitantly with a single dose of controlled-release levodopa 100 mg/benserazide 25 mg, single doses of nebicapone 50, 100, and 200 mg were well tolerated in these healthy adult volunteers, and dose dependently inhibited S-COMT activity and reduced 3-OMD formation compared with placebo. However, there was no significant difference in levodopa bioavailability.


Assuntos
Acetofenonas/farmacologia , Acetofenonas/farmacocinética , Antiparkinsonianos/farmacologia , Antiparkinsonianos/farmacocinética , Benserazida/farmacologia , Benserazida/farmacocinética , Inibidores de Catecol O-Metiltransferase , Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/farmacocinética , Levodopa/farmacologia , Levodopa/farmacocinética , Acetofenonas/administração & dosagem , Adolescente , Adulto , Área Sob a Curva , Benserazida/administração & dosagem , Catecol O-Metiltransferase/sangue , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Preparações de Ação Retardada , Método Duplo-Cego , Combinação de Medicamentos , Inibidores Enzimáticos/administração & dosagem , Feminino , Meia-Vida , Humanos , Levodopa/administração & dosagem , Masculino , Pessoa de Meia-Idade , Tirosina/análogos & derivados , Tirosina/sangue , Adulto Jovem
15.
Eur J Pharm Biopharm ; 55(1): 71-6, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12551706

RESUMO

The objective was to assess the effect of food on the pharmacokinetics of levodopa and 3-O-methyldopa after administration of a new levodopa/benserazide formulation with a dual-release drug delivery profile (Madopar DR). In an open-label, two-way cross-over study, 19 healthy volunteers who had fasted overnight were randomized to receive a single oral dose of levodopa/benserazide (200/50 mg) in the absence or presence of a standardized, high-fat breakfast, administered 30 min before drug administration. The treatment periods (fasting, non-fasting) were preceded by a baseline regimen of levodopa/benserazide (100/25 mg t.i.d. for 6 or 7 days). Blood samples were taken at specific times over a 12-hour period. Plasma concentrations of levodopa and 3-O-methyldopa were determined by high-performance liquid chromatography for pharmacokinetic evaluation. The parameter C(max) of levodopa was significantly lower and t(max) longer under postprandial conditions than under fasting conditions (mean C(max) 1.41 vs. 2.09 mg l(-1); mean t(max) 3.1 vs. 1.0 h). With food, the area under the curve (AUC) of levodopa was equivalent to that following an overnight fast. Compared with volunteers who had fasted, food did not alter t(1/2). Estimates of C(max), t(max) and AUC of 3-O-methyldopa under non-fasting conditions were not significantly different from those under fasting conditions. In conclusion, food decreases the rate of levodopa absorption, but had no effect on the systemic exposure to levodopa and the degree of 3-O-methyldopa formation. Standardization of levodopa/benserazide administration with respect to meal times is recommended.


Assuntos
Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Alimentos , Levodopa/farmacocinética , Tirosina/análogos & derivados , Adulto , Antiparkinsonianos/efeitos adversos , Antiparkinsonianos/sangue , Área Sob a Curva , Benserazida/efeitos adversos , Benserazida/sangue , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Preparações de Ação Retardada , Esquema de Medicação , Combinação de Medicamentos , Jejum , Feminino , Interações Alimento-Droga , Meia-Vida , Humanos , Levodopa/efeitos adversos , Levodopa/sangue , Masculino , Fatores de Tempo , Tirosina/sangue
16.
Eur Neurol ; 49(1): 39-44, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12464717

RESUMO

The objective was to assess the single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following administration of a new dual-release and conventional slow-release formulation of levodopa/benserazide in the dose ratio of 4:1. In an open-label, two-way cross-over study, 20 healthy volunteers were randomized to receive first either Madopar DR or Madopar HBS for 8 days. Then they crossed over to the other formulation. A first dose of 200 mg levodopa and 50 mg benserazide ('250' mg) was given on day 1, '125' mg t.i.d. on the subsequent 6 days (days 2-7), followed by '250' mg on day 8. The two treatment periods of 8 days were separated by a wash-out period of at least 7 days. Blood samples were taken at specific times over a 12-hour period (day 1) or a 36-hour period (day 8). Plasma concentrations of levodopa and 3-O-methyldopa were measured by high-performance liquid chromatography for pharmacokinetic evaluation. The pharmacokinetics of levodopa after a single-dose administration (day 1) of Madopar DR and Madopar HBS were significantly different as reflected by the respective mean values of maximum plasma concentration (C(max) 1.99 vs. 0.82 mg x l-1), time to reach maximum concentration (t(max) 0.7 vs. 2.6 h) and area under the plasma concentration-time curve (AUC(0- infinity ) 4.52 vs. 3.18 mg x h x l-1). The respective values after multiple doses (day 8) were: C(max) 1.98 vs. 0.93 mg x l-1, t(max) 0.7 vs. 2.3 h and AUC(0-infinity ) 4.84 vs. 3.96 mg x h x l-1. The relative bioavailability (Madopar DR vs. Madopar HBS) was 1.73 on day 1 and 1.32 on day 8. Bioequivalence could not be demonstrated for log-transformed data of AUC and C(max) within a predefined range of 80-125 and 70-143%, respectively. In conclusion, the observed differences in C(max), t(max) and AUC are consistent with a faster rate and higher extent of levodopa absorption after administration of Madopar DR. Statistical evaluation of these kinetic data showed that Madopar DR is not bioequivalent to Madopar HBS.


Assuntos
Antiparkinsonianos/administração & dosagem , Benserazida/administração & dosagem , Dopaminérgicos/administração & dosagem , Levodopa/administração & dosagem , Levodopa/farmacocinética , Metildopa/farmacocinética , Adulto , Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Preparações de Ação Retardada , Dopaminérgicos/farmacocinética , Relação Dose-Resposta a Droga , Esquema de Medicação , Combinação de Medicamentos , Feminino , Humanos , Masculino , Valores de Referência
17.
Pharm Res ; 18(8): 1174-84, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11587490

RESUMO

PURPOSE: To study the PK interaction of L-dopa/benserazide in rats. METHODS: Male rats received a single oral dose of 80 mg/kg L-dopa or 20 mg/kg benserazide or 80/20 mg/kg L-dopa/benserazide. Based on plasma concentrations the kinetics of L-dopa, 3-O-methyldopa (3-OMD), benserazide, and its metabolite Ro 04-5127 were characterized by noncompartmental analysis and a compartmental model where total L-dopa clearance was the sum of the clearances mediated by amino-acid-decarboxylase (AADC), catechol-O-methyltransferase and other enzymes. In the model Ro 04-5127 inhibited competitively the L-dopa clearance by AADC. RESULTS: The coadministration of L-dopa/benserazide resulted in a major increase in systemic exposure to L-dopa and 3-OMD and a decrease in L-dopa clearance. The compartmental model allowed an adequate description of the observed L-dopa and 3-OMD concentrations in the absence and presence of benserazide. It had an advantage over noncompartmental analysis because it could describe the temporal change of inhibition and recovery of AADC. CONCLUSIONS: Our study is the first investigation where the kinetics of benserazide and Ro 04-5127 have been described by a compartmental model. The L-dopa/benserazide model allowed a mechanism-based view of the L-dopa/benserazide interaction and supports the hypothesis that Ro 04-5127 is the primary active metabolite of benserazide.


Assuntos
Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Levodopa/farmacocinética , Algoritmos , Animais , Antiparkinsonianos/farmacologia , Benserazida/farmacologia , Calibragem , Carboxiliases/antagonistas & inibidores , Interações Medicamentosas , Injeções Intravenosas , Levodopa/farmacologia , Masculino , Modelos Biológicos , Ratos , Ratos Wistar
18.
Acta Neurol Scand ; 100(4): 231-7, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10510682

RESUMO

OBJECTIVES: The pharmacokinetics of free L-dopa in blood and tissue of five parkinsonian patients with malignant melanoma was studied with microdialysis. In one case the effect of L-dopa treatment on 5-S-cysteinyldopa and the melanoma was studied. Gastric emptying and its effects on free L-dopa in blood were also investigated in one of the patients. METHODS: Five patients were given 100 mg L-dopa with 25 mg benserazide. Blood and dialysates from the circulation and fatty tissue were collected for analysis. [13C]-Octanoic breath test was used for analyzing gastric half-emptying time. RESULTS: Four of the patients had similar pharmacokinetic patterns for L-dopa and a significant (P < 0.05) increase of serum 5-S-cysteinyldopa occurring 30 min after L-dopa intake. Delayed L-dopa peaks and slow gastric half-emptying time were found in 1 patient. A dose-dependent increase of 5-S-cysteinyldopa occurred but no melanoma metastases were seen during long-term L-dopa therapy. CONCLUSION: L-dopa therapy increases 5-S-cysteinyldopa levels but does not seem to cause progress of melanomas. Gastric emptying impacts L-dopa pharmacokinetics.


Assuntos
Levodopa/farmacocinética , Melanoma/complicações , Doença de Parkinson/tratamento farmacológico , Neoplasias Cutâneas/complicações , Idoso , Antiparkinsonianos/farmacocinética , Antiparkinsonianos/uso terapêutico , Benserazida/farmacocinética , Benserazida/uso terapêutico , Feminino , Humanos , Levodopa/uso terapêutico , Masculino , Microdiálise , Pessoa de Meia-Idade , Doença de Parkinson/complicações
19.
Eur J Neurol ; 6(2): 211-9, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10053234

RESUMO

This study investigated the potential interaction between tolcapone, a catechol-O-methyltransferase (COMT) inhibitor, and the decarboxylase inhibitor, benserazide. In an open-labelled six-week study, patients with Parkinson's disease (PD), treated with levodopa/benserazide, were given tolcapone at 200 mg t.i.d. Blood samples for analysis of benserazide, its main active metabolite, trihydroxybenzylhydrazine, levodopa and 3-O- methyldopa (3-OMD) were collected immediately before and repeatedly after the first drug intake of the day at baseline and after 1-2 and 6 weeks of treatment. Furthermore, animal experiments were performed to determine the levels of benserazide and trihydroxybenzylhydrazine at doses for which safety had previously been established. It was shown that tolcapone can cause an increase in benserazide plasma concentrations and that this effect is dependent on the benserazide dose. When tolcapone was combined with 25 mg benserazide the elevation was small. Although the increase was more pronounced when tolcapone was combined with 50 mg benserazide, the levels were still substantially lower than concentrations causing toxicity in animals. The safety margin derived from this study, together with the absence of any organic toxic effects in clinical trials, show that the observed interaction between tolcapone and benserazide does not represent a safety concern for PD patients treated with this combination.


Assuntos
Antiparkinsonianos/administração & dosagem , Antiparkinsonianos/farmacologia , Benserazida/administração & dosagem , Benserazida/farmacocinética , Benzofenonas/administração & dosagem , Doença de Parkinson/tratamento farmacológico , Idoso , Antiparkinsonianos/efeitos adversos , Benserazida/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Quimioterapia Combinada , Inibidores Enzimáticos/farmacocinética , Feminino , Humanos , Hidrazinas/farmacocinética , Levodopa/administração & dosagem , Levodopa/farmacocinética , Masculino , Pessoa de Meia-Idade , Nitrofenóis , Fatores de Tempo , Tolcapona , Tirosina/análogos & derivados , Tirosina/farmacocinética
20.
Clin Neuropharmacol ; 22(6): 351-5, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10626097

RESUMO

We compared the kinetic-dynamic profile of a postprandial dose of levodopa-benserazide dispersible formulation to that of the standard form in eight patients with parkinsonism presenting delayed or irregular patterns of after-meal levodopa dose effects. Patients were studied on two occasions, one week apart, according to an intra-subject randomized cross-over design. Thirty minutes after the consumption of a standard meal, patients received their usual levodopa-benserazide postprandial dose, on one occasion in the standard formulation and on the other one in the dispersible form. Blood venous samples for analysis of plasma levodopa concentrations were drawn at 15-minute intervals for the first 2 hours, then half-hourly until 5 hours after dosing. Motor response to the levodopa test dose was assessed by the finger tapping test at the same times as blood was sampled. The only statistically significant finding was a shorter time to peak plasma levodopa concentration with the levodopa-benserazide dispersible formulation compared with the standard form, whereas comparisons of levodopa pharmacodynamics showed little advantage of either formulation. Considering that liquid formulations of levodopa are less practical, we suggest reserving dispersible levodopa-benserazide tablets for selected patients and carefully monitoring drug dose motor response.


Assuntos
Antiparkinsonianos/uso terapêutico , Benserazida/uso terapêutico , Levodopa/uso terapêutico , Destreza Motora/efeitos dos fármacos , Doença de Parkinson/tratamento farmacológico , Idoso , Antiparkinsonianos/farmacocinética , Benserazida/farmacocinética , Estudos Cross-Over , Relação Dose-Resposta a Droga , Combinação de Medicamentos , Monitoramento de Medicamentos , Feminino , Humanos , Levodopa/farmacocinética , Masculino , Pessoa de Meia-Idade , Doença de Parkinson/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...